Literature DB >> 25333573

Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil.

Xiangyong Li1, Haibin Zhao2, Xijian Zhou1, Lei Song1.   

Abstract

5-Fluorouracil (5-FU) chemotherapy is widely used in the treatment of advanced colon cancer. However, the development of resistance to 5-FU is a significant obstacle to successful treatment. MicroRNA-34a (miR-34a) has been reported to be downregulated in a number of tumor types and has also been shown to act as a tumor suppressor. However, the mechanisms underlying the biological effects of miR-34a in chemoresistance remain unclear. The present study showed that the expression of miR-34a is downregulated in 5-FU-resistant colon cancer cells. In addition, 5-FU-resistant colon cancer cells exhibited upregulation of lactate dehydrogenase A (LDHA) expression and activity compared with parental cells. Furthermore, LDHA was shown to be a direct target of miR-34a. Overexpression of miR-34a reduced the expression of LDHA, probably through binding to the 3' untranslated region, leading to the re-sensitization of 5-FU-resistant cancer cells to 5-FU. Additionally, overexpression of LDHA rendered colon cancer cells resistant to 5-FU, suggesting that the miR-34a-induced sensitization to 5-FU is mediated through the inhibition of LDHA. In conclusion, the current study showed that miR-34a is involved in sensitivity to 5-FU in part through its effects on LDHA expression. This indicates that miR-34a‑mediated inhibition of glucose metabolism may be a therapeutic target in patients with chemoresistant colon cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25333573     DOI: 10.3892/mmr.2014.2726

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  37 in total

Review 1.  MicroRNA regulation and analytical methods in cancer cell metabolism.

Authors:  Ling-Fei Zhang; Shuai Jiang; Mo-Fang Liu
Journal:  Cell Mol Life Sci       Date:  2017-03-20       Impact factor: 9.261

2.  Stable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival.

Authors:  Nzinga Mack; Elizabeth A Mazzio; David Bauer; Hernan Flores-Rozas; Karam F A Soliman
Journal:  Anticancer Res       Date:  2017-03       Impact factor: 2.480

Review 3.  MicroRNAs are important regulators of drug resistance in colorectal cancer.

Authors:  Yang Zhang; Jing Wang
Journal:  Biol Chem       Date:  2017-07-26       Impact factor: 3.915

4.  MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.

Authors:  Rui Li; Xuejun Shi; Fengyu Ling; Chunguang Wang; Junxia Liu; Wei Wang; Ming Li
Journal:  Tumour Biol       Date:  2015-04-21

Review 5.  Dysregulation of metabolic enzymes in tumor and stromal cells: Role in oncogenesis and therapeutic opportunities.

Authors:  Mohammad Aslam Khan; Haseeb Zubair; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Cancer Lett       Date:  2020-01-07       Impact factor: 8.679

Review 6.  The emerging role of noncoding RNAs in colorectal cancer chemoresistance.

Authors:  Ling Wei; Xingwu Wang; Liyan Lv; Yan Zheng; Nasha Zhang; Ming Yang
Journal:  Cell Oncol (Dordr)       Date:  2019-07-29       Impact factor: 6.730

Review 7.  Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.

Authors:  María Antonia Lizarbe; Jorge Calle-Espinosa; Eva Fernández-Lizarbe; Sara Fernández-Lizarbe; Miguel Ángel Robles; Nieves Olmo; Javier Turnay
Journal:  Biomed Res Int       Date:  2017-05-10       Impact factor: 3.411

Review 8.  Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression.

Authors:  Zhaoyong Li; Huafeng Zhang
Journal:  Cell Mol Life Sci       Date:  2015-10-23       Impact factor: 9.261

Review 9.  PD-1/PD-L1 pathway: current researches in cancer.

Authors:  Yanyan Han; Dandan Liu; Lianhong Li
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

10.  Synergistically suppressive effects on colorectal cancer cells by combination of mTOR inhibitor and glycolysis inhibitor, Oxamate.

Authors:  Bao-Cheng Xing; Can Wang; Fu-Jian Ji; Xue-Bin Zhang
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.